NYSE:ATNM Actinium Pharmaceuticals (ATNM) Stock Price, News & Analysis $1.10 +0.02 (+1.85%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$1.10 0.00 (-0.09%) As of 10/9/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsNews and TrendsOptions ChainOwnershipSEC Filings About Actinium Pharmaceuticals Stock (NYSE:ATNM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ATNM alerts:Sign Up Key Stats Today's Range$1.07▼$1.1250-Day Range$0.75▼$1.4052-Week Range$0.74▼$1.74Volume105,763 shsAverage Volume146,115 shsMarket Capitalization$34.59 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company Overview Actinium Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing targeted radiotherapies for the treatment of hematologic malignancies. Its platform uses monoclonal antibodies to deliver radioactive isotopes directly to cancer cells, with the goal of selectively destroying diseased cells while reducing damage to healthy tissue. The company’s leading product candidate is Iomab-B, also known as iostamab-I-131 or apamistamab, an investigational targeted conditioning agent designed to prepare patients with relapsed or refractory acute myeloid leukemia for hematopoietic stem cell transplantation. Actinium is also developing related programs intended to address other blood cancers and to support conditioning or cell-therapy applications. Actinium Pharmaceuticals is headquartered in New York and conducts its development activities primarily through clinical research and collaborations with medical institutions. The company is led by Sandesh Seth, who serves as chairman and chief executive officer. Its therapies remain investigational and are subject to clinical and regulatory review.AI Generated. May Contain Errors. Read More Actinium Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreATNM MarketRank™: Actinium Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 620th out of 882 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingActinium Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialActinium Pharmaceuticals has a consensus price target of $5.00, representing about 354.5% upside from its current price of $1.10.Amount of Analyst CoverageActinium Pharmaceuticals has received no research coverage in the past 90 days.Read more about Actinium Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Actinium Pharmaceuticals are expected to grow in the coming year, from ($1.41) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Actinium Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Actinium Pharmaceuticals is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioActinium Pharmaceuticals has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ATNM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldActinium Pharmaceuticals does not currently pay a dividend.Dividend GrowthActinium Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentActinium Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Actinium Pharmaceuticals this week, compared to 1 article on an average week.Search Interest2 people have searched for ATNM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Actinium Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Actinium Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders0.60% of the stock of Actinium Pharmaceuticals is held by insiders.Percentage Held by Institutions27.50% of the stock of Actinium Pharmaceuticals is held by institutions.Read more about Actinium Pharmaceuticals' insider trading history. Receive ATNM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ATNM Stock News HeadlinesReviewing Actinium Pharmaceuticals (NYSE:ATNM) and Allarity Therapeutics (NASDAQ:ALLR)34 minutes ago | americanbankingnews.comActinium Pharmaceuticals (NYSE:ATNM) Shares Climb 0.9% - Still a Buy?October 9 at 2:01 AM | americanbankingnews.comThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Because my research has led me to believe we’re risking World War 3 with Iran for a completely different reason.October 11 at 1:00 AM | Banyan Hill Publishing (Ad)ATNM: Initiating Coverage – Diversified Nuclear Medicine PortfolioSeptember 15, 2026 | msn.comActinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 4, 2026 | prnewswire.comActinium Pharmaceuticals, Inc.: Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing UpdateAugust 15, 2026 | finanznachrichten.deActinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing UpdateAugust 14, 2026 | prnewswire.comActinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well ...June 4, 2026 | finance.yahoo.comSee More Headlines ATNM Stock Analysis - Frequently Asked Questions How have ATNM shares performed this year? Actinium Pharmaceuticals' stock was trading at $1.36 at the start of the year. Since then, ATNM shares have decreased by 19.1% and is now trading at $1.10. How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals, Inc. (NYSE:ATNM) released its quarterly earnings data on Monday, August, 5th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.02. When did Actinium Pharmaceuticals' stock split? Shares of Actinium Pharmaceuticals reverse split on Tuesday, August 11th 2020.The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinium Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA), Global Ship Lease (GSL), OPKO Health (OPK), Company Calendar Last Earnings8/05/2024Today10/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ATNM's financial health is in the Green zone, according to TradeSmith. ATNM has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNYSE:ATNM Previous SymbolNYSE:ATNM CIK1388320 Webactiniumpharma.com Phone(646) 677-3870FaxN/AEmployees25Year Founded2000Price Target and Rating Average Price Target for Actinium Pharmaceuticals$5.00 High Price Target$5.00 Low Price Target$5.00 Potential Upside/Downside+354.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)$0.36 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$48.82 million Net MarginsN/A Pretax Margin-50,512.35% Return on Equity-100.85% Return on Assets-47.89% Debt Debt-to-Equity RatioN/A Current Ratio10.25 Quick Ratio10.25 Sales & Book Value Annual Sales$35.09 million Price / Sales0.99 Cash FlowN/A Price / Cash FlowN/A Book Value$1.31 per share Price / Book0.84Miscellaneous Outstanding Shares31,441,000Free Float29,324,000Market Cap$34.59 million OptionableOptionable Beta0.26 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NYSE:ATNM) was last updated on 10/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinium Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinium Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
